237 related articles for article (PubMed ID: 20660846)
1. Risk profiles and treatment patterns among men diagnosed as having prostate cancer and a prostate-specific antigen level below 4.0 ng/ml.
Shao YH; Albertsen PC; Roberts CB; Lin Y; Mehta AR; Stein MN; DiPaola RS; Lu-Yao GL
Arch Intern Med; 2010 Jul; 170(14):1256-61. PubMed ID: 20660846
[TBL] [Abstract][Full Text] [Related]
2. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era.
D'Amico AV; Whittington R; Malkowicz SB; Cote K; Loffredo M; Schultz D; Chen MH; Tomaszewski JE; Renshaw AA; Wein A; Richie JP
Cancer; 2002 Jul; 95(2):281-6. PubMed ID: 12124827
[TBL] [Abstract][Full Text] [Related]
3. Many young men with prostate-specific antigen (PSA) screen-detected prostate cancers may be candidates for active surveillance.
Kim J; Ebertowski J; Janiga M; Arzola J; Gillespie G; Fountain M; Soderdahl D; Canby-Hagino E; Elsamanoudi S; Gurski J; Davis JW; Parker PA; Boyd DD
BJU Int; 2013 May; 111(6):934-40. PubMed ID: 23350937
[TBL] [Abstract][Full Text] [Related]
4. Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml.
Stamey TA; Johnstone IM; McNeal JE; Lu AY; Yemoto CM
J Urol; 2002 Jan; 167(1):103-11. PubMed ID: 11743285
[TBL] [Abstract][Full Text] [Related]
5. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249
[TBL] [Abstract][Full Text] [Related]
6. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
[TBL] [Abstract][Full Text] [Related]
7. Age and PSA predict likelihood of organ-confined disease in men presenting with PSA less than 10 ng/mL: implications for screening.
Aleman M; Karakiewicz PI; Kupelian P; Kattan MW; Graefen M; Cagiannos I; Eastham J; Scardino PT; Huland H; Klein EA
Urology; 2003 Jul; 62(1):70-4. PubMed ID: 12837425
[TBL] [Abstract][Full Text] [Related]
8. Maximum tumor diameter and the risk of prostate-specific antigen recurrence after radical prostatectomy.
Rose BS; Chen MH; Zhang D; Hirsch MS; Richie JP; Chang SL; Hegde JV; Loffredo MJ; D'Amico AV
Clin Genitourin Cancer; 2014 Oct; 12(5):e173-9. PubMed ID: 24787967
[TBL] [Abstract][Full Text] [Related]
9. Three-year postoperative ultrasensitive prostate-specific antigen following open radical retropubic prostatectomy is a predictor for delayed biochemical recurrence.
Malik RD; Goldberg JD; Hochman T; Lepor H
Eur Urol; 2011 Sep; 60(3):548-53. PubMed ID: 21652145
[TBL] [Abstract][Full Text] [Related]
10. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.
Corcoran NM; Casey RG; Hong MK; Pedersen J; Connolly S; Peters J; Harewood L; Gleave ME; Costello AJ; Hovens CM; Goldenberg SL
BJU Int; 2012 Jul; 110(1):36-42. PubMed ID: 22085203
[TBL] [Abstract][Full Text] [Related]
11. Stage T1-2 prostate cancer with pretreatment prostate-specific antigen level < or = 10 ng/ml: radiation therapy or surgery?
Keyser D; Kupelian PA; Zippe CD; Levin HS; Klein EA
Int J Radiat Oncol Biol Phys; 1997 Jul; 38(4):723-9. PubMed ID: 9240638
[TBL] [Abstract][Full Text] [Related]
12. Prediagnostic prostate-specific antigen velocity and probability of detecting high-grade prostate cancer.
Krejcarek SC; Chen MH; Renshaw AA; Loffredo M; Sussman B; D'Amico AV
Urology; 2007 Mar; 69(3):515-9. PubMed ID: 17382156
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy.
Kupelian PA; Elshaikh M; Reddy CA; Zippe C; Klein EA
J Clin Oncol; 2002 Aug; 20(16):3376-85. PubMed ID: 12177097
[TBL] [Abstract][Full Text] [Related]
14. Identification of factors predicting response to adjuvant radiation therapy in patients with positive margins after radical prostatectomy.
Kamat AM; Babaian K; Cheung MR; Naya Y; Huang SH; Kuban D; Babaian RJ
J Urol; 2003 Nov; 170(5):1860-3. PubMed ID: 14532793
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases.
Partin AW; Pearson JD; Landis PK; Carter HB; Pound CR; Clemens JQ; Epstein JI; Walsh PC
Urology; 1994 May; 43(5):649-59. PubMed ID: 7513108
[TBL] [Abstract][Full Text] [Related]
16. Association between PSA values and surveillance quality after prostate cancer surgery.
Chapman CH; Caram MEV; Radhakrishnan A; Tsodikov A; Deville C; Burns J; Zaslavsky A; Chang M; Leppert JT; Hofer T; Sales AE; Hawley ST; Hollenbeck BK; Skolarus TA
Cancer Med; 2019 Dec; 8(18):7903-7912. PubMed ID: 31691526
[TBL] [Abstract][Full Text] [Related]
17. Pre-operative percent free PSA predicts clinical outcomes in patients treated with radical prostatectomy with total PSA levels below 10 ng/ml.
Shariat SF; Abdel-Aziz KF; Roehrborn CG; Lotan Y
Eur Urol; 2006 Feb; 49(2):293-302. PubMed ID: 16387412
[TBL] [Abstract][Full Text] [Related]
18. Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy.
Zhou P; Chen MH; McLeod D; Carroll PR; Moul JW; D'Amico AV
J Clin Oncol; 2005 Oct; 23(28):6992-8. PubMed ID: 16192586
[TBL] [Abstract][Full Text] [Related]
19. Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer.
D'Amico AV; Whittington R; Malkowicz SB; Fondurulia J; Chen MH; Kaplan I; Beard CJ; Tomaszewski JE; Renshaw AA; Wein A; Coleman CN
J Clin Oncol; 1999 Jan; 17(1):168-72. PubMed ID: 10458230
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
